Literature DB >> 7710929

Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.

M W Sark1, H Timmer-Bosscha, C Meijer, D R Uges, W J Sluiter, W H Peters, N H Mulder, E G de Vries.   

Abstract

Cisplatin (CDDP) resistance mechanisms were studied in a model of three germ cell tumour and three colon carcinoma cell lines representing intrinsically CDDP-sensitive and -resistant tumours respectively. The CDDP sensitivity of the cell lines mimicked the clinical situation. The glutathione levels of the cell lines correlated with CDDP concentrations inhibiting cell survival by 50% (IC50); total cellular sulphydryl content (TSH) was unexpectedly inversely correlated with IC50. IC50 correlated neither with glutathione S-transferase (GST) nor with GST pi expression, topoisomerase I or II activity. Immediately after 4 h incubation with CDDP, platinum (Pt) accumulation and Pt bound to DNA were not correlated, but after another 24 h drug-free culture, Pt binding to DNA in germ cell tumour but not in colon carcinoma cell lines correlated with IC50. With the exception of in vitro sensitivity and TSH, none of the parameters studied discriminated between the two groups of cell lines. Correction of CDDP sensitivity parameters for phenotypical differences did not influence statistical correlations. Analysis of variance revealed a correlation between IC50 and the combination of glutathione, GST activity and Pt bound to DNA. But at other CDDP cytotoxicity levels sensitivity was also correlated with Pt accumulation, topoisomerase II activity and TSH in various combinations. This model of intrinsic CDDP resistance showed that multiple parameters ought to be studied to explain CDDP resistance, but did not elucidate the cause of the unique sensitivity of germ cell carcinoma, although the unexpected values of TSH deserve further attention.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710929      PMCID: PMC2033748          DOI: 10.1038/bjc.1995.135

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

Review 1.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

Authors:  P A Andrews; S B Howell
Journal:  Cancer Cells       Date:  1990-02

2.  Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein.

Authors:  J Koropatnick; J Pearson
Journal:  Mol Pharmacol       Date:  1993-07       Impact factor: 4.436

Review 3.  The molecular basis of cisplatin sensitivity/resistance.

Authors:  L R Kelland
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

4.  An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines.

Authors:  L K Hosking; R D Whelan; S A Shellard; P Bedford; B T Hill
Journal:  Biochem Pharmacol       Date:  1990-10-15       Impact factor: 5.858

5.  Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line.

Authors:  H Timmer-Bosscha; G A Hospers; C Meijer; N H Mulder; F A Muskiet; I A Martini; D R Uges; E G de Vries
Journal:  J Natl Cancer Inst       Date:  1989-07-19       Impact factor: 13.506

6.  Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.

Authors:  R J Fram; B A Woda; J M Wilson; N Robichaud
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

7.  Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines.

Authors:  K McLaughlin; G Coren; J Masters; R Brown
Journal:  Int J Cancer       Date:  1993-02-20       Impact factor: 7.396

8.  Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs.

Authors:  J R Masters; E J Osborne; M C Walker; C N Parris
Journal:  Int J Cancer       Date:  1993-01-21       Impact factor: 7.396

9.  cis-diamminedichloroplatinum(ii) resistance in vitro and in vivo in human embryonal carcinoma cells.

Authors:  H Timmer-Bosscha; A Timmer; C Meijer; E G de Vries; B de Jong; J W Oosterhuis; N H Mulder
Journal:  Cancer Res       Date:  1993-12-01       Impact factor: 12.701

10.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.

Authors:  S de Jong; J G Zijlstra; E G de Vries; N H Mulder
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

View more
  8 in total

1.  Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.

Authors:  Roelof Koster; Alessandra di Pietro; Hetty Timmer-Bosscha; Johan H Gibcus; Anke van den Berg; Albert J Suurmeijer; Rainer Bischoff; Jourik A Gietema; Steven de Jong
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

2.  Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent.

Authors:  Alessandra di Pietro; Roelof Koster; Wytske Boersma-van Eck; Wendy A Dam; Nanno H Mulder; Jourik A Gietema; Elisabeth G E de Vries; Steven de Jong
Journal:  Cell Cycle       Date:  2012-11-19       Impact factor: 4.534

3.  Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Authors:  Caryl J Giuliano; Sarah J Freemantle; Michael J Spinella
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

Review 4.  Molecular mechanisms behind the resistance of cisplatin in germ cell tumours.

Authors:  Josep Ma Piulats; Laura Jiménez; Xavier García del Muro; Alberto Villanueva; Francesc Viñals; José R Germà-Lluch
Journal:  Clin Transl Oncol       Date:  2009-12       Impact factor: 3.405

5.  Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.

Authors:  B Nitzsche; C Gloesenkamp; M Schrader; B Hoffmann; F Zengerling; S Balabanov; F Honecker; M Höpfner
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

6.  Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.

Authors:  R Koster; H Timmer-Bosscha; R Bischoff; J A Gietema; S de Jong
Journal:  Cell Death Dis       Date:  2011-04-21       Impact factor: 8.469

7.  Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy.

Authors:  C Meijer; E G de Vries; W A Dam; M H Wilkinson; H Hollema; H J Hoekstra; N H Mulder
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines.

Authors:  H Burger; K Nooter; A W Boersma; C J Kortland; G Stoter
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.